Preventing metastases to bone: denosumab or bisphosphonates?
Nanes
Mark S
MS
Atlanta, VA Medical Center and Emory University School of Medicine, Decatur, GA, USA. mnanes@emory.edu
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary; D003131:Combined Modality Therapy; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D053245:RANK Ligand / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab